Stocksigma LogoStocksigma Logo

Neuland Laboratories Reports Mixed Q2FY27 Results Amid Robust H1 Growth

Neuland Laboratories reported standalone total income of ₹457.2 Cr for Q2FY27, down 11.4% YoY. EBITDA declined 33.4% YoY to ₹104.6 Cr, with margins

Neuland Laboratories Reports Mixed Q2FY27 Results Amid Robust H1 Growth

Neuland Laboratories Ltd · Investor Presentation · 03 Nov 2026, 9:54 pm

Neuland Laboratories Reports Mixed Q2FY27 Results Amid Robust H1 Growth Neuland Laboratories reported standalone total income of ₹457.2 Cr for Q2FY27, down 11.4% YoY. EBITDA declined 33.4% YoY to ₹104.6 Cr, with margins contracting 754 bps YoY to 22.9% due to operating deleverage. PAT fell 47.0% YoY to ₹51.1 Cr, while diluted EPS stood at ₹39.9. Conversely, H1FY27 total income grew 35.6% YoY to ₹1,107.2 Cr, and PAT rose 80.2% YoY to ₹198.5 Cr. Net cash stood at ₹208.0 Cr. Active CMS projects reached 99, supported by ongoing capex in peptides and R&D.

Original exchange filing (PDF)

More announcements from Neuland Laboratories Ltd

All Neuland Laboratories Ltd announcements